Type 2 17-β Hydroxysteroid Dehydrogenase as a Novel Target for the Treatment of Osteoporosis

References

• Harvey R , FerrierD. Biochemistry (Lippincott Illustrated Reviews Series) (5th Edition). Lippincott Wiliams & Wikins, MD, USA (2010).
   Google Scholar
• Murray R , GrannerD, MayesP, RodwellV. Harper's Illustrated Biochemistry (26th Edition). The McGraw-Hill Companies, Inc., NY, USA (2003).
   Google Scholar
• Koos R . Minireview: putting physiology back into estrogens’ mechanism of action. Endocrinology152 (12), 4481–4488 (2011).
   PubMed Web of Science ®Google Scholar
• Simpson R , MissoM, HewittNet al. Estrogen – the good, the bad, and the unexpected. Endocr. Rev.26, 322–330 (2005).
   PubMed Web of Science ®Google Scholar
• Gruber CJ , TschugguelW, SchneebergerC, HuberJC. Mechanisms of disease: production and actions of estrogens. N. Engl. J. Med.346, 340–352 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrucci L , MaggioM, BandinelliSet al. Low Testosterone levels and the risk of anemia in older men and women. Arch. Intern. Med.166, 1380–1388 (2006).
   PubMed Web of Science ®Google Scholar
• Snyder P , PeacheyH, BerlinJet al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab.85, 2670–2677 (2000).
   PubMed Web of Science ®Google Scholar
• Burger H . How effective is testosterone replacement therapy in premenopausal women with severe androgen deficiency?Nat. Clin. Pract. Endocrinol. Metab.2, 432–433 (2006).
   Google Scholar
• Nadkarni S , CooperD, BrancaleoneV, BenaS, PerrettiM. Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes. Arterioscler. Thromb. Vasc. Biol.31, 2749–2759 (2011).
   PubMed Web of Science ®Google Scholar
• Rosano GM , PaninaG. Oestrogens and the heart. Therapie54, 381–385 (1999).
   PubMed Web of Science ®Google Scholar
• Carani C , QinK, SimoniMet al. Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med.337, 91–95 (1997).
   PubMed Web of Science ®Google Scholar
• Meethal SV , LiuT, ChanHWet al. Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors. J. Neurochem.110, 1014–1027 (2009).
   PubMed Web of Science ®Google Scholar
• Douma SL , HusbandC, O'DonnellME, BarwinBN, WoodendAK. Estrogen-related mood disorders: reproductive life cycle factors. ANS Adv. Nurs. Sci.28, 364–375 (2005).
   PubMed Web of Science ®Google Scholar
• Lasiuk GC , HegadorenKM. The effects of estradiol on central serotonergic systems and its relationship to mood in women. Biol. Res. Nurs.9, 147–160 (2007).
   PubMed Web of Science ®Google Scholar
• Vlahopoulos S , ZimmerWE, JensterG. Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J. Bio. Chem.280, 7786–7792 (2005).
   PubMed Web of Science ®Google Scholar
• Zuloaga DG , PutsDA, JordanCL, BreedloveSM. The role of androgen receptors in the masculinization of brain and behavior: what we've learned from the testicular feminization mutation. Horm. Behav.53, 613–626 (2008).
   PubMed Web of Science ®Google Scholar
• Singh R , ArtazaJN, TaylorWEet al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology147, 141–154 (2006).
   PubMed Web of Science ®Google Scholar
• Burtis C , AshwoodE, BrunsD. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier Inc., MO, USA (2005).
   Google Scholar
• Stocco D . Star protein and the regulation of steroid hormone biosynthesis. Annu. Rev. Physiol.63, 193–213 (2001).
   PubMed Web of Science ®Google Scholar
• Miller W , AuchusR. The molecular biology biochemistry and physiology of human steroidogenesis and its disorders. Endocr. Rev.32, 81–151 (2011).
   PubMed Web of Science ®Google Scholar
• Burger H . Androgen production in women. Fertil. Steril.77, S3–S5 (2002).
   PubMed Web of Science ®Google Scholar
• Lukacik P , KavanaghKL, OppermannU. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol.248, 61–71 (2006).
   PubMed Web of Science ®Google Scholar
• Mindnich R , MöllerG, AdamskiJ. The role of 17 beta-hydroxysteroid dehydrogenases. Mol. Cell. Endo.218, 7–20 (2004).
   PubMed Web of Science ®Google Scholar
• Peltoketo H , Luu-TheV, SimardJ, AdamskiJ. 17 -Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family, nomenclature and main characteristics of the 17HSD/KSR enzymes. J. Mol. Endocrinol.23, 1–11 (1999).
   PubMed Web of Science ®Google Scholar
• Wu L , EinsteinM, GeisslerWM, ChanHK, EllistonKO, AnderssonS. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2 a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J. Biol. Chem.268, 12964–12969 (1993).
   PubMed Web of Science ®Google Scholar
• Manolagas SC . Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev.21, 115–137 (2000).
   PubMed Web of Science ®Google Scholar
• Marcus R . Agents affecting calcification and bone turnover. In : Goodman and Gilman's Pharmacological Basis of Therapeutics. McGraw-Hill, NY, USA, 1519–1545 (1995).
   Google Scholar
• Nijweidi Peter J , FeyenJH. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol. Rev.66 (4), 855–886 (1986).
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL . Bone resorption by osteoclasts. Science289, 1504–1508 (2000).
   PubMed Web of Science ®Google Scholar
• Murthy R , MorrowP, TheriaultR. Bone biology and the role of the rank ligand pathway. Oncology23, 9–15 (2009).
   PubMed Web of Science ®Google Scholar
• Albright F , SmithP, RichardsonA. Postmenopausal osteoporosis: its clinical features. JAMA116, 2465–2474 (1941).
   Google Scholar
• Carruba G1 , AdamskiJ, CalabròMet al. Molecular expression of 17β hydroxysteroid dehydrogenase types in relation to their activity in intact human prostate cancer cells. Mol. Cell. Endocrinol.131, 51–57 (1997).
   PubMed Web of Science ®Google Scholar
• Cassey ML , MacDonaldPC, AnderssonS. 17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. J. Clin. Invest.94, 2135–2141 (1994).
   PubMed Web of Science ®Google Scholar
• Miettinen MM , MustonenMVJ, PoutanenMH, IsomaaVV, VihkoRK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell-and tissue-specific expression. Biochem. J.314, 839–845 (1995).
   Web of Science ®Google Scholar
• Mustonen M , PoutanenM, Chotteau-LelievreAet al. Ontogeny of 17β-hydroxysteroid dehydrogenase type 2 mRNA expression in the developing mouse placenta and fetus. Mol. Cell. Endocrinol.134, 33–40 (1997).
   PubMed Web of Science ®Google Scholar
• Mustonen MVJ , PoutanenMH, KellokumpuSet al. Mouse 17 beta-hydroxysteroid dehydrogenase type 2 mRNA is predominantly expressed in hepatocytes and in surface epithelial cells of the gastrointestinal and urinary tracts. J. Mol. Endocrinol.20, 67–74 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng YH , ImirA, FenkciV, YilmazMB, BulunSE. Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism. Am. J. Obstet. Gynecol.196, 391.e1–7 (2007).
   PubMed Web of Science ®Google Scholar
• Yang S , FangZ, GuratesB. Stromal progesterone receptors mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol. Endocrinol.15, 2093–2105 (2001).
   PubMed Web of Science ®Google Scholar
• Day JM , TutillHJ, NewmanSPet al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2: association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol.248, 246–249 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng YH , YinP, XueQ, YilmazB, DawsonMI, BulunSE. « Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism. J. Clin. Endocrinol Metab.93, 1915–1923 (2008).
   PubMed Web of Science ®Google Scholar
• Zhongyi S , RantakariP, LamminenT, ToppariJ, PoutanenM. Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids. Endocrinology148, 3827–3836 (2007).
   PubMed Web of Science ®Google Scholar
• Alberts B , JohnsonA, LewisJ, RaffM, RobertsK, WalterP. Molecular Biology of the Cell (5th Edition). Garland Science, NY, USA (2007).
   Google Scholar
• Thiboutot D , MartinP, VolikosL, GillilandL. Oxidative activity of the type 2 isozyme of 17β-hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands. J. Invest. Dermatol.111, 390–395 (1998).
   PubMed Web of Science ®Google Scholar
• Sonnhammer E L , von HeijneG, KroghA. A hidden Markov model for predicting transmembrane helices in protein sequences. Proc. Int. Conf. Intell. Syst. Mol. Biol.6, 175–182 (1998).
   PubMedGoogle Scholar
• Casey ML , MacDonaldPC, AnderssonS. 17β-hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. J. Clin. Invest.94, 2135–2141 (1994).
   PubMed Web of Science ®Google Scholar
• Luu-The V . Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase. J. Steroid. Biochem. Mol. Biol.67, 143–151 (2001).
   Google Scholar
• Mutschler E , Schäfer-KortingM. Arzneimittelwirkungen (8th Edition). Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany (2001).
   Google Scholar
• Delaforge M , PruvostA, PerrinL, AndréF. Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17β-glucuronide oxidation to 2-hydroxy-estradiol-17β-glucuronide by CYP 2c8. Drug Metab. Dispos, 33 (3), 466–473 (2004).
   PubMed Web of Science ®Google Scholar
• Lu ML , HuangYW, LinSX. Purification reconstitution and steady-state kinetics of the trans-membrane 17 beta-hydroxysteroid dehydrogenase 2. J. Biol. Chem.277, 22123–22130 (2002).
   PubMed Web of Science ®Google Scholar
• Drolet R , SimardM, PlanteJ, LabergeP, TremblayY. Human type 2 17 beta-hydroxysteroid dehydrogenase mRNA and protein distribution in placental villi at mid and term pregnancy. Reprod. Biol. Endocrinol.5, 30 (2007).
   PubMed Web of Science ®Google Scholar
• Mustonen M , PoutanenM, Chotteau-LelievreAet al. Ontogeny of 17 β hydroxysteroid dehydrogenase type 2 mRNA expression in the developing mouse placenta and fetus. Mol. Cell. Endocrinol.134, 33–40 (1997).
   PubMed Web of Science ®Google Scholar
• Simard M1 , PlanteJ, BoucherM, ProvostPR, TremblayY. Type 2 and 5 17beta-hydroxysteroid dehydrogenases and androgen receptor in human fetal lungs. Mol. Cell. Endocrinol.319, 79–87 (2010).
   PubMed Web of Science ®Google Scholar
• Zeitoun K1 , TakayamaK, SasanoHet al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J. Clin. Endocrinol Metab.83, 4474–4480 (1998).
   PubMed Web of Science ®Google Scholar
• Noble LS , SimpsonER, JohnsA, BulunSE. Aromatase expression in endometriosis. J. Clin. Endocrinol. Metab.81, 174–179 (1996).
   PubMed Web of Science ®Google Scholar
• Noble LS , TakayamaK, PutmanJM. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J. Clin. Endocrinol. Metab.82, 600–606 (1997).
   PubMed Web of Science ®Google Scholar
• Simpson ER , ZhaoY, AgarwalVR. Aromatase expression in healthand disease. Recent Prog. Horm. Res.52, 185–214 (1997).
   PubMedGoogle Scholar
• Bulun SE , NobleLS, TakayamaK. Endocrine disorders associated with inappropriately high aromatase expression. J. Steroid. Biochem. Mol. Biol.61, 133–139 (1997).
   PubMed Web of Science ®Google Scholar
• Ono YJ , TeraiY, TanabeAet al. Decorin induced by progesterone plays a crucial role in suppressing endometriosis. J. Endocrinol.223, 203–216 (2014).
   PubMed Web of Science ®Google Scholar
• Tamaresis JS , IrwinJC, GoldfienGAet al. Molecular classification of endometriosis and disease stage using high-dimensional genomic data. Endocrinology155, 4986–4999 (2014).
   PubMed Web of Science ®Google Scholar
• Zito G , LuppiS, GioloEet al. Medical treatments for endometriosis-associated pelvic pain. Biomed. Res. Int.2014, 191967 (2014).
   PubMed Web of Science ®Google Scholar
• Shen F , YanC, LiuM, FengY, ChenY. Decreased expression of mucin-1 in endometriosis endometrium correlated with progesterone receptor B involved in infertility. Arch. Gynecol. Obstet.291 (2), 439–445 (2014).
   PubMed Web of Science ®Google Scholar
• Oliveira IO , LhullierC, BrumIS, SpritzerPM. Gene expression of type 2 17 beta hydroxysteroid dehydrogenase in scalp hairs of hirsute women. Steroids68, 641–649 (2003).
   PubMed Web of Science ®Google Scholar
• Rantakari P , StraussL, KivirantaR, LagerbohmH, PavialaJ, HolopainenI. Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene. Mol. Endocrinol.22 (3), 665–675 (2008).
   Web of Science ®Google Scholar
• Travis R , KeyK. Oestrogen exposure and breast cancer risk. Breast Cancer Res.5, 239–247 (2003).
   PubMed Web of Science ®Google Scholar
• Oduwole OO , LiY, IsomaaVVet al. 17Beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res.64, 7604–7609 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki T , MoriyaT, ArigaN, KanekoC, KanazawaM, SasanoH. 17Betahydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br. J. Cancer82, 518–523 (2000).
   PubMed Web of Science ®Google Scholar
• Gunnarsson C , OlssonBM, StålO. Abnormal expression of 17betahydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res.61, 8448–8451 (2001).
   PubMed Web of Science ®Google Scholar
• Gunnarsson C , HellqvistE, StålO. 17Beta-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast. Br. J. Cancer92, 547–552 (2005).
   PubMed Web of Science ®Google Scholar
• Jansson A . 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J. Steroid Biochem. Mol. Biol.114, 64–67 (2009).
   PubMed Web of Science ®Google Scholar
• Yaeger R , NolanPC, SuTet al. 17 β HSD 2 may be higher in African–American breast cancer and is associated with estrogen receptor-negative tumors. Cancer Geno Prots.4, 341–348 (2007).
   PubMedGoogle Scholar
• Ito K , UtsunomiyaH, SuzukiTet al. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol. Cell. Endocrinol.248, 136–140 (2006).
   PubMed Web of Science ®Google Scholar
• Sasano H , SuzukiT, NiikuraHet al. 17 beta-hydroxysteroid dehydrogenase in common epithelial ovarian tumors. Mod. Pathol.9, 386–391 (1996).
   PubMed Web of Science ®Google Scholar
• Feix M , WolfL, SchweikertHU. Distribution of 17β-hydroxysteroid dehydrogenases in human osteoblast-like cells. Mol. Cell. Endocrinol.171, 163–164 (2001).
   PubMed Web of Science ®Google Scholar
• Du Z , SteckR, DoanN, WoodruffM, IvanovskiS, XiaoY. Estrogen deficiency associated bone loss in the maxilla: a methodology to quantify the changes in the maxillary intra-radicular alveolar bone in an ovariectomized rat osteoporosis model. Tissue. Eng. Part. C Methods21 (5), 458–466 (2014).
   PubMed Web of Science ®Google Scholar
• Van Caenegem E , WierckxK, TaesYet al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos. Int.26, 35–47 (2015).
   PubMed Web of Science ®Google Scholar
• Ward KA , RobertsSA, AdamsJE, MughalMZ. Bone geometry and density in the skeleton of pre-pubertal gymnasts and school children. Bone36, 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• McCarthy TL , CentrellaM. Prostaglandin dependent control of an endogenous estrogen receptor agonist by osteoblasts. J. Cell. Physiol.230, 1104–14 (2015).
   PubMed Web of Science ®Google Scholar
• Swift SN , SwiftJM, BloomfieldSA. Mechanical loading increases detection of estrogen receptor-alpha in osteocytes and osteoblasts despite chronic energy restriction. J. Appl. Physiol.117, 1349–1355 (2014).
   PubMed Web of Science ®Google Scholar
• Gourlay M , RichyF, ReginsterJ. Strategies for the prevention of hip fracture. Am. J. Med.115, 309–317 (2003).
   PubMed Web of Science ®Google Scholar
• Body J . How to manage postmenopausal osteoporosis?Acta Clin. Belg, 66 (6), 443–447 (2011).
   PubMed Web of Science ®Google Scholar
• Wells GA , CranneyA, PetersonJet al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev.23 (1), CD001155 (2008).
   Google Scholar
• Lin J , LaneJ. Osteoporosis: a review. Clin. Orthop.425, 126–134 (2004).
   PubMed Web of Science ®Google Scholar
• Yates J , Barrett-ConnorE, BarlasSet al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet. Gynecol.103 (3), 440–446 (2004).
   PubMed Web of Science ®Google Scholar
• Delmas P . Treatment of postmenopausal osteoporosis. Lancet359, 2018–2026 (2002).
   PubMed Web of Science ®Google Scholar
• Grobbee D . LIFT study to continue as planned. BMJ331, 843 (2005).
   PubMedGoogle Scholar
• Reginster J . Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J. Intern. Med.255, 615–628 (2004).
   PubMed Web of Science ®Google Scholar
• WHO . Prevention and management of osteoporosis. WHO Tech. Rep. Ser.92, 1–164 (2003).
   Google Scholar
• Åkesson K . New approaches to pharmacological treatment of osteoporosis. Bull. WHO81, 657–664 (2003).
   PubMed Web of Science ®Google Scholar
• Sambrook PN , SeemanE, PhillipsSRet al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med. J. Aust.176, S1–S16 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen C , BilezikianJ. Clinical review 123: Hot Topic: anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab.86 (3), 957–964 (2001).
   PubMed Web of Science ®Google Scholar
• Adams J , PeppingJ. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am. J. Health-Syst. Pharm.62, 1574–1581 (2005).
   PubMed Web of Science ®Google Scholar
• McClung M , LewieckiM, CohenSet al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med.354, 821–831 (2006).
   PubMed Web of Science ®Google Scholar
• Bagi CM , WoodJ, WilkieD, DixonB. Effect of 17β-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys. J. Musculoskelet. Neuronal. Interact.8, 267–280 (2008).
   PubMedGoogle Scholar
• Puranen TJ , KurkelaRM, LakkakorpiJT. Characterization of molecular and catalytic properties of intact and truncated human 17β-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Endocrinology140, 3334–3341 (1999).
   PubMed Web of Science ®Google Scholar
• Luu-The V , ZhangY, PoirierD, LabrieF. Characteristics of human types 1 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol.55, 581–587 (1995).
   PubMed Web of Science ®Google Scholar
• Zhu BT , HanGZ, ShimJY, WenY, JiangXR. Quantitative structure–activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology147, 4132–4150 (2006).
   PubMed Web of Science ®Google Scholar
• Qiu W , CampbellRL, GangloffAet al. A concerted rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. FASEB J.16, 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Wood J , BagiC, AkucheCet al. 4 5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17β-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. Bioorg. Med. Chem. Lett.16, 4965–4968 (2006).
   PubMed Web of Science ®Google Scholar
• Knittel J , ZavodR. Drug design and relationship of functional groups to pharmacologic activity. In : Foye's Principles of Medicinal Chemistry (6th Edition). Lippincott Williams & Wilkins, NY, USA, 26–52 (2008).
   Google Scholar
• Deluca D , KrazeisenA, BreitlingR, PrehnC, MöllerG, AdamskiJ. Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens:Comparison with other steroid metabolizing enzymes. J. Steroid Biochem. Mol. Biol.93, 285–292 (2005).
   PubMed Web of Science ®Google Scholar
• Le Bail JC , ChampavierY, ChuliaAJ, HabriouxG. Effects ofphytoestrogens on aromatase 3beta and 17beta-hydroxysteroid dehydrogenaseactivities and human breast cancer cells. Life Sci.66, 1281–1291 (2000).
   PubMed Web of Science ®Google Scholar
• Le Bail JC , LarocheT, Marre-FournierF, HabriouxG. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett.133, 101–106 (1998).
   PubMed Web of Science ®Google Scholar
• Kristan K , KrajncK, KoncJ, GobecS, StojanJ, RiznerTL. Phytoestrogens as inhibitors of fungal 17beta-hydroxysteroid dehydrogenase. Steroids.70 (10), 694–703 (2005).
   PubMed Web of Science ®Google Scholar
• Auger S , Luu-TheV, Mane SamK, PoirierD. 3-Hydroxy-19-nor-17α-pregna-1 3 5(10)-triene-21 17β-carbolactone as inhibitor of 17β-hydroxysteroid dehydrogenase type 2. Bioorg. Med. Chem. Lett.4, 2045–2048 (1994).
   Web of Science ®Google Scholar
• Sam KM , AugerS, Luu-TheV, PoirierD. Steroidal Spiro-.gamma.-lactones that inhibit 17.beta.-hydroxysteroid dehydrogenase activity in human placental microsomes. J. Med. Chem.38, 4518–4528 (1995).
   PubMed Web of Science ®Google Scholar
• Poirier D , BydalP, TremblayM, Luu-TheV. Inhibitors of type II 17β-hydroxysteroid dehydrogenase. Mol. Cell. Endocrinol.171 (1–2), 119–128 (2001).
   PubMed Web of Science ®Google Scholar
• Bydal P , AugerS, PoirierD. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure–activity relationships. Steroids69, 325–342 (2004).
   PubMed Web of Science ®Google Scholar
• Sam KM , LabrieF, PoirierD. N-Butyl-N-methyl-11-(3’-hydroxy-21’ 17’-carbolactone-19’-nor-17’α-pregna-1’ 3’ 5’(10’)-trien-7’α-yl)-undecanamide: an inhibitor of type 2 17β-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur. J. Med. Chem.35, 217–225 (2000).
   PubMed Web of Science ®Google Scholar
• Xu K , WetzelM, HartmannR, Marchais-OberwinklerS. Spiro-δ-lactones as Inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2). Lett. Drug Des. Disc.8, 406–421 (2011).
   Web of Science ®Google Scholar
• Hoffmann M , RychlewskiJ. When, in the context of drug design, can a fluorine atom successfully substitute a hydroxyl group?Int. J. Quantum Chem.48 (4), 419–427 (2002).
   Google Scholar
• Deluca D , MöllerG, RosinusA, ElgerW, HillischA, AdamskiJ. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol.248, 218–224 (2006).
   PubMed Web of Science ®Google Scholar
• Cook J , BarzyaJ, BrennanCet al. 4 5-disubstituted cis-pyrrolidinones as inhibitors of 17β-hydroxysteroid dehydrogenase II. Part 1: synthetic approach. Tetrahed. Lett.46, 1525–1528 (2005).
   Web of Science ®Google Scholar
• Gunn D , AkucheC, BaryzaJet al. 4 5-disubstituted cis-pyrrolidinones as inhibitors of type II 17β-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg. Med. Chem. Lett.15, 3053–3057 (2005).
   PubMed Web of Science ®Google Scholar
• Bey E , Marchais-OberwinklerS, KruchtenPet al. Design synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bioorg. Med. Chem.16, 6423–6435 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Soud Y , BeyE, OsterAet al. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 and type 2. Mol. Cell. Endocrinol.301, 212–215 (2009).
   PubMed Web of Science ®Google Scholar
• Bey E , Marchais-OberwinklerS, KruchtenPet al. New Insights into the SAR and binding modes of Bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitory activity and selectivity. J. Med. Chem.52, 6724–6743 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Soud YA , Marchais-OberwinklerS, FrotscherM, HartmannRW. Synthesis and biological evaluation of phenyl substituted 1H-1 2 4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2. Arch. Pharm. (Weinheim)345, 610–621 (2012).
   PubMed Web of Science ®Google Scholar
• Xu K , Al-SoudYA, WetzelM, HartmannRW, Marchais-OberwinklerS. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors. Eur. J. Med. Chem.46, 5978–5990 (2011).
   PubMed Web of Science ®Google Scholar
• Marras G , MetrangoloP, MeyerF, PilatiT, ResnatG, VijA. Solid state synthesis under supramolecular control of a 2D heterotetratopic self-complementary tecton tailored to halogen bonding. New Journal of Chemistry30, 1397–1402 (2006).
   Web of Science ®Google Scholar
• Marchais-Oberwinkler S , XuK, WetzelMet al. Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis. J. Med. Chem, 56 (1), 167–181 (2013).
   PubMed Web of Science ®Google Scholar
• Perspicace E , CozzoliL, GarganoEMet al. Novel potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities. Eur. J. Med. Chem.83, 317–337 (2014).
   PubMed Web of Science ®Google Scholar
• Gargano EM , PerspicaceE, HankeN, CarottiA, Marchais-OberwinklerS, HartmannRW. Metabolic stability optimization and metabolite identification of 2 5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors. Eur. J. Med. Chem.87C, 203–219 (2014).
   Google Scholar
• Wetzel M , GarganoEM, HinsbergerS, Marchais-OberwinklerS, HartmannRW. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis. Eur. J. Med. Chem.47, 1–17 (2012).
   PubMed Web of Science ®Google Scholar
• Oster A , HinsbergerS, WerthR, Marchais-OberwinklerS, FrotscherM, HartmannRW. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem.53, 8176–8186 (2010).
   PubMed Web of Science ®Google Scholar
• Oster A , KleinT, HennCet al. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. Chem. Med. Chem.6, 476–487 (2011).
   Google Scholar
• Perspicace E , GiorgioA, CarottiA, Marchais-OberwinklerS, HartmannRW. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors with good ADME-related physicochemical parameters. Eur. J. Med. Chem.69, 201–215 (2013).
   PubMed Web of Science ®Google Scholar
• Frotscher M , ZieglerE, Marchais-OberwinklerSet al. Design synthesis and biological evaluation of (Hydroxyphenyl)naphtalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem.51, 2158–2169 (2008).
   PubMed Web of Science ®Google Scholar
• Wetzel M , Marchais-OberwinklerS, HartmannRW. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold. Bioorg. Med. Chem.19, 807–815 (2011).
   PubMed Web of Science ®Google Scholar
• Wetzel M , Marchais-OberwinklerS, PerspicaceE, MöllerG, AdamskiJ, HartmannRW. Introduction of an electron withdrawing group on the hydroxyphenylnaphtol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors. J. Med. Chem.54, 7547–7557 (2011).
   PubMed Web of Science ®Google Scholar
• Vuorinen A , EngeliR, MeyerAet al. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase2 inhibitors. J. Med. Chem.57, 5995–6007 (2014).
   PubMed Web of Science ®Google Scholar
• Papapoulos S . Inhibition of sclerostin in the management of osteoporosis: results of a Phase 2 clinical trial meet expectations. Bonekey Rep.3, 523 (2014).
   PubMedGoogle Scholar
• Negishi-Koga T , ShinoharaM, KomatsuNet al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. J. Nat. Med.17 (11), 1473–1480 (2011).
   Google Scholar
• Zhang Y , WeiL, MironR, ZhangQ, BianZ. Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J. Dent. Res.93 (11), 1095–1100 (2014).
   PubMed Web of Science ®Google Scholar
• Hamdy NA . Osteoprotegerin as a potential therapy for osteoporosis. Curr. Osteoporos. Rep.3 (4), 121–125 (2005).
   PubMedGoogle Scholar